On Friday, Baird adjusted its outlook on Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares, reducing the price target to $4 from the previous $5 while maintaining a Neutral stance on the stock.
The decision came after Mersana announced its first-quarter earnings for 2024, revealing ongoing developments in its Phase 1 trial of XMT-1660, a B7-H4 antibody-drug conjugate (ADC).
The trial has shown responses in the dose escalation and back-fill study, but a maximum tolerated dose (MTD) has yet to be established. The company now anticipates initial data and the beginning of dose expansion to occur in the second half of 2024, a slight delay from the previously expected mid-2024 timeframe.
The Baird analyst highlighted the delay as a minor one, but also noted that it does not bolster confidence in the potential for positive data from the trial. The analyst's cautious stance is further influenced by the competitive landscape, as XMT-1660 is up against similar developments from three major pharmaceutical companies.
Despite the observed responses in the trial, the delay in data and dose expansion has led to Baird's continued neutral position on Mersana's stock. The firm remains watchful of the drug's ability to show distinct advantages over its competitors' offerings.
Mersana's share price target adjustment reflects the current assessment of the company's progress and the competitive challenges it faces in the development of its ADC. The company's next significant update is now slated for the latter half of 2024, which will be a critical period for evaluating the drug's clinical potential and its impact on Mersana's market position.
InvestingPro Insights
As investors digest the latest developments from Mersana Therapeutics, Inc. (NASDAQ:MRSN), real-time data and insights from InvestingPro could provide additional context. The company's market capitalization stands at $301.62 million, with a significant Price / Book multiple of 8.17, reflecting the market's valuation of the company's assets relative to its share price. Despite an 18.4% revenue growth over the last twelve months as of Q1 2024, Mersana's gross profit margin has been deeply negative at -287.15%, indicating substantial costs relative to revenue.
InvestingPro Tips suggest caution, with analysts not expecting profitability this year and noting that the stock is in oversold territory according to the Relative Strength Index (RSI). Additionally, the company has been quickly burning through cash, which could be a concern for investors looking at the long-term viability of the company. With the stock having taken a significant hit over the last week and month, it's worth noting that there are 12 additional InvestingPro Tips available for Mersana, which can be found at Investing.com/pro/MRSN. For those interested in a deeper dive into Mersana's financial health and market standing, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.